We use cookies to make your experience better. To comply with the new e-Privacy directive, we need to ask for your consent to set the cookies. Learn about our cookie policy.
Cell Signaling Ctla-4 (E5s7e) Rabbit mAb
List Price
$351.00
Your Price
$351.00
Cell Signaling Ctla-4 (E5s7e) Rabbit mAb - CSSPQ (Additional S&H or Hazmat Fees May Apply)
NETA PART:
CSSPQ-50490S
MFG.PART:
50490S
UNSPSC:
12352203
Manufacturer:
Cell Signaling
| Size | 100 µl |
| Reactivity | M |
| Sensitivity | Endogenous |
| Source/Isotype | Rabbit IgG |
| Application/Dilution | {Immunofluorescence (Frozen): 1:200 - 1:800} |
| Storage | Supplied in 10 mm sodium HEPES (pH 7.5), 150 mm NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody. |
| Specificity/Sensitivity | CTLA-4 (E5S7E) Rabbit mAb recognizes endogenous levels of total mouse CTLA-4 protein. |
| Species Reactivity | Mouse |
| Source/Purification | Monoclonal antibody is produced by immunizing animals with recombinant protein specific to the extracellular domain of mouse CTLA-4 protein. |
| Background | Cytotoxic T-lymphocyte protein 4 (CTLA-4, CD152) is an Ig superfamily member that negatively regulates early T cell activation (1-4). The CTLA-4 protein is primarily expressed on T cells, including CD8+ cytotoxic T cells, CD4+ helper T cells, and CD4+/FoxP3+ regulatory T cells (1,2). CTLA-4 protein competes with CD28 for B7.1 (CD80) and B7.2 (CD86) binding at the cell surface, which results in the downregulation of T cell activity (5). The activation of SHP-2 and PP2A downstream of CTLA-4 attenuates TCR signaling (6). Research studies indicate that CTLA4 knockout mice display lymphoproliferative disorders leading to early death, confirming the role of CTLA-4 as a negative regulator of T cells (7). Mutations in the corresponding CTLA4 gene are associated with multiple disorders, including insulin-dependent diabetes mellitus, Graves disease, Hashimoto thyroiditis, celiac disease, systemic lupus erythematosus, and type V autoimmune lymphoproliferative syndrome (8,9). Additional studies demonstrate that CTLA-4 blockade is an effective strategy for tumor immunotherapy (10-12). |
| SKU | CSSPQ-50490S |
|---|---|
| Supplier Part Number | 50490S |
| UM | EA |
| UNSPSC | 12352203 |
| Manufacturer | Cell Signaling |
| MSDS URL | Click here |
| Temperature | -20C |
| CountryOfOrigin | United States |
| ProductLine | CSSPQ |
| Qty | 1 |
| MinOrderQty | 1 |
| Weight | 7.000000 |
| Lead Time | 5 |
| Hazardous | N |
| Energy Star | No |
| Green | No |
| Controlled | N |